Idactamab
- Generic Name
- Idactamab
A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors
Phase 1
Completed
- Conditions
- Non Small Cell Lung Cancer Squamous (NSCLC-Sq)Head and Neck Squamous Cell Carcinoma (HNSCC)Small Cell Lung Cancer (SCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Interventions
- First Posted Date
- 2019-01-22
- Last Posted Date
- 2019-12-30
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 8
- Registration Number
- NCT03811652
- Locations
- 🇨🇦
Research Site, Toronto, Ontario, Canada
A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies
Phase 1
Completed
- Conditions
- Acute Myeloid LeukemiaDiffuse Large B-cell LymphomaMultiple Myeloma
- Interventions
- First Posted Date
- 2017-04-10
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 67
- Registration Number
- NCT03106428
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath